Hologic Inc.
Hologic Reports Q1 FY2025 Financial Results
Summary
Hologic, Inc. announced its financial results for the first quarter of fiscal year 2025. The company reported GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.03, in line with guidance. Total revenue for the quarter was $1,021.8 million, a 0.9% increase from the prior year, and constant currency growth was 1.0%. Despite the revenue growth, Hologic lowered its full-year GAAP EPS guidance due to currency headwinds and weakness in breast health capital sales, while maintaining its non-GAAP EPS guidance.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement